There is a massive price variation among different brands of the same generic ACE inhibitors and ARBs in India, highlighting the need for physicians to prescribe cost-effective options to improve adherence.
Clinicians should factor brand costs into ACEI/ARB prescribing for hypertension; leaves open effects on adherence and outcomes.
Objective: Hypertension is a chronic disorder requiring lifelong treatment. This study is done to find out the percentage variation of cost among different brands of angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) used in hypertension.
No takes yet. Share an insight, caveat, or question.
Gujjarlamudi et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: